AAA604 / Novartis, PeptiDream - LARVOL DELTA

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=24 | Terminated | Sponsor: Novartis Pharmaceuticals | Active, not recruiting ➔ Terminated; The decision was not based on any safety concerns

Trial termination • Brain Cancer • CNS Tumor • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Jan 2027 ➔ Dec 2024 | Trial primary completion date: Jan 2027 ➔ Dec 2024

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=6 | Active, not recruiting | Sponsor: Novartis Pharmaceuticals | Recruiting ➔ Active, not recruiting | N=116 ➔ 6

Enrollment change • Enrollment closed • Metastases • Brain Cancer • CNS Tumor • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=116 | Recruiting | Sponsor: Novartis Pharmaceuticals | Trial completion date: Apr 2026 ➔ Jan 2027 | Trial primary completion date: Apr 2026 ➔ Jan 2027

Metastases • Trial completion date • Trial primary completion date • Brain Cancer • CNS Tumor • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor

A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=116 | Recruiting | Sponsor: Novartis Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Metastases • Brain Cancer • CNS Tumor • Esophageal Adenocarcinoma • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Glioblastoma • Oncology • Pancreatic Cancer • Solid Tumor